Effects of supplementation with omega-3 fatty acids on oxidative stress and inflammation in patients with Alzheimer's disease: The OmegAD study

Journal of Alzheimer's Disease

Volumn 42, Issue 3, 2014, Pages 823-831

  Freund Levi, Yvonne ^a   Vedin, Inger ^b   Hjorth, Erik ^a   Basun, Hans ^c,d   Faxén Irving, Gerd ^b   Schultzberg, Marianne ^a   Eriksdotter, Maria ^a   Palmblad, Jan ^b   Vessby, Bengt ^e   Wahlund, Lars Olof ^a   Cederholm, Tommy ^e   Basu, Samar ^d,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; eicosanoids; F2 isoprostane; inflammation; lipids; omega 3 fatty acids; oxidative stress; prostaglandin F2

Indexed keywords

15 KETO DIHYDRO PROSTAGLANDIN F2 ALPHA; 8 ISOPROSTAGLANDIN F2 ALPHA; ARACHIDONIC ACID; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; PROSTAGLANDIN F2 ALPHA; UNCLASSIFIED DRUG; CYTOKINE; ISOPROSTANE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DIET SUPPLEMENTATION; FEMALE; HORMONE BLOOD LEVEL; HORMONE URINE LEVEL; HUMAN; INFLAMMATION; MALE; MINI MENTAL STATE EXAMINATION; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; COGNITION DISORDERS; COMPLICATION; DEPRESSION; DIET THERAPY; DRUG EFFECTS; METABOLISM; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; RETROSPECTIVE STUDY; URINE;

ADMINISTRATION, ORAL; AGED; ALZHEIMER DISEASE; COGNITION DISORDERS; CYTOKINES; DEPRESSION; DIETARY SUPPLEMENTS; DINOPROST; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; F2-ISOPROSTANES; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; OXIDATIVE STRESS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES;

EID: 84907155927     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-132042     Document Type: Article

References (43)

1. Brayne C, Barker RA, Harold D, Ince PG, Savva GM, Williams J, Williams-Gray CH, Wharton SB (2013) From molecule to clinic and community for neurodegeneration: Research to bridge translational gaps. J Alzheimers Dis 33(Suppl 1), S385-S396.
2. Norton S, Matthews FE, Brayne C (2013) A commentary on studies presenting projections of the future prevalence of dementia. BMC Public Health 13, 1.
3. Marlatt MW, Webber KM, Moreira PI, Lee HG, Casadesus G, Honda K, Zhu X, Perry G, Smith MA (2005) Therapeutic opportunities in Alzheimer disease: One for all or all for one? Curr Med Chem 12, 1137-1147.
4. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2, a006346.
5. Perry G, Smith MA (1998) Is oxidative damage central to the pathogenesis of Alzheimer disease? Acta Neurol Belg 98, 175-179.
6. Basu S (2008) F2-isoprostanes in human health and diseases: From molecular mechanisms to clinical implications. Antioxid Redox Signal 10, 1405-1434.
7. Smedman A, Vessby B, Basu S (2004) Isomer-specific effects of conjugated linoleic acid on lipid peroxidation in humans: Regulation by alpha-tocopherol and cyclooxygenase-2 inhibitor. Clin Sci (Lond) 106, 67-73.
8. Varvel NH, Bhaskar K, Kounnas MZ, Wagner SL, Yang Y, Lamb BT, Herrup K (2009) NSAIDs prevent, but do not reverse, neuronal cell cycle reentry in a mouse model of Alzheimer disease. J Clin Invest 119, 3692-3702.
9. Cole GM, Lim GP, Yang F, Teter B, Begum A, Ma Q, Harris-White ME, Frautschy SA (2005) Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging 26(Suppl 1), 133-136.
10. Morris MC, EvansDA, Bienias JL, Tangney CC, BennettDA, Wilson RS, Aggarwal N, Schneider J (2003) Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60, 940-946.
11. Freund-LeviY, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial. Arch Neurol 63, 1402-1408.
12. Lim GP, Calon F, Morihara T, Yang F, Teter B, Ubeda O, Salem N, Jr., Frautschy SA, Cole GM (2005) A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25, 3032-3040.
13. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
14. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11(Suppl 2), S13-S21.
15. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314.
16. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134, 382-389.
17. Basu S (1998) Radioimmunoassay of 8-iso-prostaglandin F2alpha: An index for oxidative injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 58, 319-325.
18. Basu S (1998) Radioimmunoassay of 15-keto-13,14-dihydroprostaglandin F2alpha: An index for inflammation via cyclooxygenase catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 58, 347-352.
19. Blennow K, Wallin A, Chong JK (1995) Cerebrospinal fluid 'neuronal thread protein' comes from serum by passage over the blood-brain barrier. Neurodegeneration 4, 187-193.
20. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52.
21. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680.
22. Boberg M, Vessby B, Croon LB (1985) Fatty acid composition of platelets and of plasma lipid esters in relation to platelet function in patients with ischaemic heart disease. Atherosclerosis 58, 49-63.
23. Calder PC (2009) Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie 91, 791-795.
24. Mori TA,Woodman RJ, BurkeV, Puddey IB, Croft KD, Beilin LJ (2003) Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 35, 772-781.
25. Nalsen C, Vessby B, Berglund L, Uusitupa M, Hermansen K, Riccardi G, Rivellese A, Storlien L, Erkkila A, Yla-Herttuala S, Tapsell L, Basu S (2006) Dietary (n-3) fatty acids reduce plasma F2-isoprostanes but not prostaglandin F2alpha in healthy humans. J Nutr 136, 1222-1228.
26. Morrow JD (2000) The isoprostanes: Their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 32, 377-385.
27. Kim KM, Jung BH, Paeng KJ, Kim I, Chung BC (2004) Increased urinary F(2)-isoprostanes levels in the patients with Alzheimer's disease. Brain Res Bull 64, 47-51.
28. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, Terry E, Roberts LJ, 2nd, Kaye JA, Morrow JD (2002) Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 52, 175-179.
29. Sundelof J, Kilander L, Helmersson J, Larsson A, Ronnemaa E, Degerman-Gunnarsson M, Sjogren P, Basun H, Lannfelt L, Basu S (2009) Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: A prospective population-based study. J Alzheimers Dis 18, 71-78.
30. Casadesus G, Smith MA, Basu S, Hua J, Capobianco DE, Siedlak SL, Zhu X, Perry G (2007) Increased isoprostane and prostaglandin are prominent in neurons in Alzheimer disease. Mol Neurodegener 2, 2.
31. Montine TJ, Peskind ER, Quinn JF, Wilson AM, Montine KS, Galasko D (2011) Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Med 13, 37-43.
32. Pratico D, V MYL, Trojanowski JQ, Rokach J, Fitzgerald GA (1998) Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB J 12, 1777-1783.
33. Basu S (1998) Metabolism of 8-iso-prostaglandin F2alpha. FEBS Lett 428, 32-36.
34. Johnston H, Boutin H, Allan SM (2011) Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem Soc Trans 39, 886-890.
35. Sundelof J, Kilander L, Helmersson J, Larsson A, Ronnemaa E, Degerman-Gunnarsson M, Basun H, Lannfelt L, Basu S (2009) Systemic inflammation and the risk of Alzheimer's disease and dementia: A prospective population-based study. J Alzheimers Dis 18, 79-87.
36. Tobinick E, Gross H, Weinberger A, Cohen H (2006) TNFalpha modulation for treatment of Alzheimer's disease: A 6-month pilot study. MedGenMed 8, 25.
37. Freund-Levi Y, Hjorth E, Lindberg C, Cederholm T, Faxen-Irving G, Vedin I, Palmblad J, Wahlund LO, Schultzberg M, Basun H, Eriksdotter Jonhagen M (2009) Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: The OmegAD study. Dement Geriatr Cogn Disord 27, 481-490.
38. Kalmijn S, Feskens EJ, Launer LJ, Kromhout D (1997) Polyunsaturated fatty acids, antioxidants, and cognitive function in very old men. Am J Epidemiol 145, 33-41.
39. Jicha GA, Markesbery WR (2010) Omega-3 fatty acids: Potential role in the management of early Alzheimer's disease. Clin Interv Aging 5, 45-61.
40. Cederholm T, Palmblad J (2010) Are omega-3 fatty acids options for prevention and treatment of cognitive decline and dementia? Curr Opin Clin Nutr Metab Care 13, 150-155.
41. Hooijmans CR, Pasker-de Jong PC, de Vries RB, Ritskes-Hoitinga M (2012) The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's disease: A systematic review and meta-analysis. J Alzheimers Dis 28, 191-209.
42. Crozier SR, Inskip HM, Godfrey KM, Robinson SM (2008) Dietary patterns in pregnant women: A comparison of foodfrequency questionnaires and 4 d prospective diaries. Br J Nutr 99, 869-875.
43. Garcia-Rodriguez CE, Helmersson-Karlqvist J, Mesa MD, Miles EA, Noakes PS, Vlachava M, Kremmyda LS, Diaper ND, Godfrey KM, Calder PC, Gil A, Basu S (2011) Does increased intake of salmon increase markers of oxidative stress in pregnant women? The salmon in pregnancy study. Antioxid Redox Signal 15, 2819-2823.